A PROSPECTIVE INTERVENTIONAL COMPARATIVE LONG-TERM STUDY ON THE EFFICACY OF CANAGLIFLOZIN AND DAPAGLIFLOZIN IN A TERTIARY CARE HOSPITAL FOR A SPAN OF 1 YEAR

A PROSPECTIVE INTERVENTIONAL COMPARATIVE LONG-TERM STUDY ON THE EFFICACY OF CANAGLIFLOZIN AND DAPAGLIFLOZIN IN A TERTIARY CARE HOSPITAL FOR A SPAN OF 1 YEAR DHANUSH BELLAPU RONALD DARWIN

Objectives: This study mainly focuses on the comparison between the efficacy of canagliflozin and dapagliflozin by observing the prolonged effects, quality of life of patients, and comparing them with patients prescribed antihyperglycemic agents other than sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Methods: This prospective interventional comparative study was conducted among 3452 patients admitted to the general medicine and endocrine department, Anu Group of Hospitals, Vijayawada, for 1 year, by eluding the patient’s fasting blood sugar, postprandial blood sugar, renal function test, Hemoglobin A1c, blood pressure, and the finding severity score of adverse drug reaction (ADR) using the Naranjo scale during the study. Results: The most common ADRs after utilizing canagliflozin was hypotension and dapagliflozin wes dehydration. The Chi-square test for patients with ADR’s after using canagliflozin versus dapagliflozin used to treat type 2 diabetes. 9.12529 is the calculated Chi-square value at 5° of freedom and 5% level of significance (p<0.1042 – not significant). This shows that there was a slight difference but similar effects using canagliflozin versus dapagliflozin. The positive effect after treatment was weight reduction, which was greater in canagliflozin. Negative effects were hypotension, dehydration, infections, polyuria, and ketoacidosis, which were greater in canagliflozin. Conclusion: We concluded that females were affected by urinary tract infection and vaginal infection. Efficacy was similar in control, canagliflozin, and dapagliflozin, but it may be a cost-related burden.
07 07 2025 147 151 http://creativecommons.org/licenses/by/4.0 10.22159/ajpcr.2025v18i7.54767 https://journals.innovareacademics.in/index.php/ajpcr/article/view/54767 https://journals.innovareacademics.in/index.php/ajpcr/article/download/54767/32242 https://journals.innovareacademics.in/index.php/ajpcr/article/download/54767/32242 10.1038/clpt.2011.16 Pfister M, Whaley JM, Zhang L, List JF. Inhibition of SGLT2: A novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011;89(4):621-5. doi: 10.1038/clpt.2011.16, PMID 21346749 Chinnakadoori SR, Reddy SM, Bodapati A, Madhuri Kallam SD, Dharmamoorthy G, Gupta JK, et al. Biological exploration of ((substituted-phenyl-1H-pyrazol-4-yl) methylene) aniline derivatives as potential DPP-IV inhibitors: ADMET screening, molecular docking, and dynamics simulations. Chem Methodol. 2025;9(1):52-80. Aminu KS, Uzairu A, Abechi SE, Shallangwa GA, Umar AB. A search for novel antidiabetic agents using ligand-based drug design and molecular docking studies employing human intestinal maltase-glucoamylase as model enzyme. Adv J Chem Sect A. 2023;6(2):155-71. 10.1056/NEJMoa2107038 Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451-61. doi: 10.1056/NEJMoa2107038, PMID 34449189 Nakka S, Gadthey S, Seema A, Marapakala K. Green assessment of stability indicating RP-HPLC method for simultaneous estimation of metformin, empagliflozin, and linagliptin in bulk and fixed dosage forms using AGREE and GAPI tools. Asian J Green Chem. 2024;8(5):623-41. Muralidharan V, Sachdeo RA, Singh LP, Haque MA, Panigrahy UP, Mishra AK, et al. Molecular docking and dynamic simulation with ADMET exploration of natural products atlas compound library to search for potential alpha amylase inhibitors for the T2DM treatment. Chem Methodol. 2025;9(2):81-102. 10.22159/ijap.2024v16i5.51084 Yadav NK, Mazumder R, Rani A, Kumar A. Current perspectives on using nanoparticles for diabetes management. Int J Appl Pharm. 2024;16(5):38-45. doi: 10.22159/ijap.2024v16i5.51084 10.22159/ijpps.2023v15i6.48019 Behera BP. Sen RK. A study on the prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus in a tertiary centre in a tribal population of eastern India. Int J Pharm Pharm Sci. 2023;15(6):29-34. 10.1001/jama.2020.1906 Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020 Apr 14;323(14):1353-68. doi: 10.1001/ jama.2020.1906, PMID 32219386 ADA. Statistics about Diabetes: American Diabetes Association®. American Diabetes Association Diabetes State; 2017. Available from: https://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav 10.58809/HBJV7965 Patel J. Diabetes, a Global Epidemic. John Heinrichs Sch Creat Act Day; 2023. Available from: https://scholars.fhsu.edu/sacad/vol2023/ iss2023/103. 10.22159/ijcpr.2024v16i6.5091 Narwat A, Goyal A, Bhati R. A systematic review on adherence to oral antidiabetic drugs in patients with type 2 diabetes mellitus. Int J Curr Pharm Res. 2024;16(6):16-8. 10.22159/ajpcr.2022.v15i8.45000 Shekhar R. A cross-sectional study of thyroid disorder in patients with type 2 diabetes mellitus in a tertiary care hospital. Asian J Pharm Clin Res. 2022;15(8):46-50. 10.7326/M19-0085 Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Ann Intern Med. 2019 Jun 4;170(11):764-9. doi: 10.7326/M19-0085, PMID 31060053 10.25258/ijddt.14.2.06 Samiya SS, Saha S, Jakhmola V, Gairola N, Singh M. Molecular docking, synthesis, antiproliferative activity against MCF-7, and in-vitro alpha amylase activities of newer generation pyrimidino hydroxamic acid derivatives. Int J Drug Deliv Technol. 2024;14(2):649-59. doi: 10.25258/ijddt.14.2.06 10.1016/S2213-8587(16)00052-8 Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8, PMID 27009625 Alifah K, Wiyono N, Arifianto H. Bibliometric analysis and content review of current perspective on heart failure with mildly reduced ejection fraction therapy. J Med Chem Sci. 2024;7:2003-15. 10.1056/NEJMoa1611925 Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. doi: 10.1056/ NEJMoa1611925, PMID 28605608 10.1080/00325481.2018.1423852 Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Postgrad Med. 2018;130(2):149-53. doi: 10.1080/00325481.2018.1423852, PMID 29297732 10.36628/ijhf.2022.0030 Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: A review of current evidence. Int J Heart Fail. 2023;5(2):82-90. doi: 10.36628/ijhf.2022.0030, PMID 37180562 10.1161/CIRCULATIONAHA.118.037778 Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-95. doi: 10.1161/CIRCULATIONAHA.118.037778, PMID 30586757 10.1161/CIRCULATIONAHA.117.032038 Mahaffey KW, Neal B, Perkovic V, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323-34. doi: 10.1161/CIRCULATIONAHA.117.032038, PMID 29133604 10.3390/ijms18051083 Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083. doi: 10.3390/ijms18051083, PMID 28524098 10.22159/ijap.2025v17i1.52573 Patil SM, Manu G, Ramya CM, Rajashekhara S, Desai SM, Parameswaran S, et al. Exploring jackfruit flour polyphenols as promising sglt-2 inhibitors for hyperglycemia management. Int J Appl Pharm. 2025;17(1):199-208. doi: 10.22159/ijap.2025v17i1.52573 10.1515/jom-2020-0153 Nelinson DS, Sosa JM, Chilton RJ. Sglt2 inhibitors: A narrative review of efficacy and safety. J Osteopath Med. 2021;121(2):229-39. doi: 10.1515/jom-2020-0153, PMID 33567084 10.1016/j.ijcard.2025.133079 Kani R, Miyamoto Y, Saito T, Watanabe A, Matsubara K, Ejiri K, et al. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis. Int J Cardiol. 2025 May;426:133079. doi: 10.1016/j. ijcard.2025.133079, PMID 39983878 10.2337/db12-0052 Liu JJ, Lee TW, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199-204. doi: 10.2337/db12-0052, PMID 22923645 10.3109/0886022X.2013.766560 Deshmukh AB, Patel MC, Mishra B. SGLT2 inhibition: A novel prospective strategy in treatment of diabetes mellitus. Ren Fail. 2013;35(4):566-72. doi: 10.3109/0886022X.2013.766560, PMID 23438184 10.1016/j.diabres.2014.02.014 Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014, PMID 24735709 10.2337/dc13-0467 Jabbour SA. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Ther Res. 2016;37(4):392-3. 10.2337/dc11-0606 Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22. doi: 10.2337/ dc11-0606, PMID 21816980 10.1111/dom.13152 Inagaki N, Harashima SI, Kaku K, Kondo K, Maruyama N, Otsuka M, et al. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2018 Apr 5;20(4):812-20. doi: 10.1111/dom.13152, PMID 29110384 Rochmah N, Perwitasari RK, Hisbiyah Y, Rosyidah LN, Ni’mah NL, Kusumastuti NP, et al. Factors affecting insulin-like growth factor-1 in type 1 diabetes mellitus in children. J Med Pharm Chem Res. 2025;7(1):120-8.